Hormones and Hormone Antagonists: Mechanisms of Action in Carcinogenesis of Endometrial and Breast Cancer

Proliferation of breast and endometrial cells is under the control of ovarian steroid hormones (SHs) such as oestrogen and progesterone. They mediate diverse physiological functions via interaction with nuclear-localised steroid hormone receptors (HRs). The SH receptor complex modifies the expression of SH-regulated genes by binding to conserved binding sites in their promoter region or through cross-talk with other transcription factors. In non-malignant tissues, HRs are in balance with other factors regulating proliferation, differentiation and apoptosis. While dysfunction of the regulatory mechanisms is a part of malignant transformation, functional SH receptors can promote growth of SH-responsive tumours. Therefore, anti-hormones that block the interaction of steroid hormones with the SH receptor are useful tools for the treatment of SH-responsive carcinomas. However, a portion of ER-positive breast cancers and most endometrial cancers do not respond to anti-oestrogens and continued treatment results in hormone resistance, mostly without loss of the ER. This review focuses on the mechanisms of action of hormones and anti-hormones in breast and endometrial carcinomas.

Breast Cancer - Endometrial Cancer - Steroid Hormone Receptors

References

• 1 Beatson G T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases.  Lancet. 1896;  2 104-207
• 2 Lacassagne A. Apparition de cancers de la mamelle chez la souris mâle, soumise à des injections de folliculine C.  R Acad Sci. 1932;  195 630-632
• 3 Lupulescu A. Oestrogene use and risk: a review.  Exp Clin Endocrin Diabetes. 1993;  101 204-214
• 4 Beckmann M W, Niederacher D, Schnurch H G, Gusterson B A, Bender H G. Multistep carcinogenesis of breast cancer and tumour heterogeneity.  J Mol Med. 1997;  75 429-439
• 5 Cohen S M, Ellwein L B. Genetic errors, cell proliferation, and carcinogenesis.  Cancer Res. 1991;  51 6493-6505
• 6 Devilee P, Cornelisse C J. Somatic genetic changes in human breast cancer.  Biochim Biophys Acta. 1996;  1198 113-130
• 7 Goldhirsch A, Glick J H, Gelber R D, Senn H J. Meeting highlights: International consensus panel on the treatment of primary breast cancer.  J Natl Cancer Inst. 1998;  90 1601-1608
• 8 Osborne C K. Tamoxifen in the treatment of breast cancer.  N Engl J Med. 1998;  339 1609-1618
• 9 Cook L S, Weiss N S, Schwartz S M, White E, McKnight B, Moore D E, Daling J R. Population-based study tamoxifen therapy and subsequent ovarian, endometrial, and breast cancer.  J Natl Cancer Inst. 1995;  87 1359-1364
• 10 Cuenca R E, Giachino J, Arredondo M A, Hempling R, Edge S B. Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use.  Cancer. 1996;  77 2058-2063
• 11 Delmas P D, Bjarnason N H, Mitlak B H, Ravoux A C, Shah A S, Huster W J, Draper M, Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women (see comments).  N Engl J Med. 1997;  337 1641-1647
• 12 . Early Breast Cancer Trialists’ Collaborative Group . Tamoxifen for early breast cancer: an overview of the randomised trials.  Lancet. 1998;  351 1451-1467
• 13 Fisher B, Costantino J P, Wickerham D L, Redmond C K, Kavanah M, Cronin W M, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.  J Natl Cancer Inst. 1998;  90 1371-1388
• 14 Ragaz J, Coldman A. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes.  J Clin Oncol. 1998;  16 2018-2024
• 15 Smith D C, Prentice R, Thompson D J, Herrmann W L. Association of exogenous oestrogen and endometrial carcinoma.  N EngI J Med. 1975;  293 1164-1167
• 16 . The Writing Group for the PEPI Trial . Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The postmenopausal oestrogen/progestin interventions (PEPI) trial.  JAMA. 1996;  275 370-375
• 17 Voigt L F, Weiss I SIS, Chu J, Daling J R, McKnight B, van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer.  Lancet. 1991;  338 274-277
• 18 Van Leeuwen F E, Rokus M A. The role of exogenous hormones in the epidemiology of breast ovarian and endometrial breast cancer.  Eur J Cancer Clin Oncol. 1989;  25 1961-1972
• 19 Belchetz P E. Hormonal treatment of postmenopausal women.  N Engl J Med. 1994;  330 1062-1071
• 20 Colditz G A, Hankinson S E, Hunter D J, Willett W C, Manson J E, Stampfer M J, Hennekens C, Rosner B, Speizer F E. The use of oestrogens and progestins and the risk of breast cancer in postmenopausal women.  N Engl J Med. 1995;  332 1589-1593
• 21 . Collaborative Group on Hormonal Factors in Breast Cancer . Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer.  Lancet. 1997;  350 1047-1059
• 22 Roy J A, Sawka C A, Pritchard K I. Hormone replacement therapy in women with breast cancer. Do the risks outweigh the benefits?.  J Clin Oncol. 1996;  14 997-1006
• 23 Peluso J J. Placing Progesterone in the apoptotic pathway.  TEM. 1997;  8 267-271
• 24 Ciocca D R, Vargas Roig L M, Fanelli M A. Oestrogen receptors in the human femal genital tract in normal and pathological conditions.  Biocell. 1994;  18 1-21
• 25 Kokawa K, Shikone T, Nakano R. Apoptosis in the human uterine endometrium during the menstrual cycle.  J Clin Endocrinol Metab. 1996;  181 4144-4147
• 26 Beckmann M W, Hanstein B, Niederacher D, Jap D, Kuschel B, Bender M G. Mechanisms of ovarian steroid hormones and antioestrogens in the development of carcinomas of the breast and endometrium.  Geburtsh Frauenheilk. 2000;  60 71-76
• 27 Kahn S A, Rogers M AM, Khurana K K, Meguid M M, Numan P J. Oestrogen receptor expression in benign breast epithelium and breast cancer risk.  J Nat Cancer Inst. 1997;  189 37-42
• 28 Beckmann M W, Niederacher D, Bender H G. Mechanisms of steroid hormone action and resistance in endometrial and breast cancer.  Eur J Cancer Prev. 1998;  7 S25-S28
• 29 Jordan V C. Anti-oestrogenic action of raloxifene and tamoxifen: today and tomorrow.  J Natl Cancer Inst. 1998;  90 967-971
• 30 Evans R M. The steroid and thyroid hormone receptor superfamily.  Science. 1988;  240 889-895
• 31 Ming J T, O’Mally. Molecular mechanisms of action of steroid/thyroid receptor superfamily members.  Annu Rev Biochem. 1994;  63 451-486
• 32 Kuiper G G, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J A. Cloning of a novel receptor expressed in rat prostate and ovary.  Proc Natl Acad Sci USA. 1996;  93 5925-5930
• 33 Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human oestrogen receptor.  FEBS Left. 1996;  392 49-53
• 34 Tremblay G B, Tremblay A, Copeland N G, Gilbert D J, Jenkins N A, Labrie F, Giguere V. Cloning, chromosomal localization, and functional analysis of the murine oestrogen receptor beta.  Mol Endocrinol. 1997;  11 353-365
• 35 Ogawa S, Inoue S, Watanabe T, Hiroi H, Orimo A, Hosoi T, Ouchi Y, Muramatsu M. The complete primary structure of human oestrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro.  Biochem Biophys Res Commun. 1998;  243 122-126
• 36 Beato M, Herrlich P, Schutz G. Steroid hormone receptors: many actors in search of a plot.  Cell. 1995;  83 851-857
• 37 Parker M G. Steroid and related receptors.  Curr Opin Cell Biol. 1993;  5 499-504
• 38 May F E, Westley B R. Oestrogen regulated messenger RNAs in human breast cancer cells.  Biomed Pharmacother. 1995;  49 400-414
• 39 Gaub M P, Bellard M, Scheurer I, Chambon P, Sassone C P. Activation of the ovalbumine gene by the estorgen receptor involves the fos jun complex.  Cell. 1996;  63 1267-1276
• 40 Philips A, Teyssier C, Galtier F, Rivier-Covas C, Rey J M, Rochefort H, Chalbos D. FRA-1 expression level modulates regulation of activator protein-1 activity by estradiol in breast cancer cells.  Mol Endocrinol. 1998;  12 973-985
• 41 Umayahara Y, Kawamori R, Watada H, Imano E, Iwama N, Morishima T, Yamasaki Y, Kajimoto Y, Kamada T. Oestrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer.  J Biol Chem. 1994;  269 16 433-16 442
• 42 Paech K, Webb P, Kuiper G G, Nilsson S, Gustafsson J, Kushner P J, Scanlan T S. Differential ligand activation of oestrogen receptors ERalpha and ERbeta at AP1 sites.  Science. 1997;  277 1508-1510
• 43 Lee S K, Kim H J, Kim J W, Lee J W. Steroid receptor coactivator-1 and its family members differentially regulate transactivation by the tumor suppressor protein p53.  Mol Endocrinol. 1999;  13 1924-1933
• 44 Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, Lin S C, Heyman R A, Rose D W, Glass C K, Rosenfeld M G. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors.  Cell. 1996;  85 403-414
• 45 Gottlicher M, Heck S, Herrlich P. Transcriptional cross-talk, the second mode of steroid hormone receptor action.  J Mol Med. 1998;  76 480-489
• 46 Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M. Oestrogen receptor-associated proteins: possible mediators of hormone-induced transcription.  Science. 1994;  264 1455-1458
• 47 Horwitz K B, Jackson T A, Bain D L, Richer J K, Takimoto G S, Tung L. Nuclear receptor coactivators and corepressors.  Mol Endocrinol. 1996;  10 1167-1177
• 48 Leo C, Chen J D. The SRC family of nuclear receptor coactivators.  Gene. 2000;  245 1-11
• 49 Onate S A, Tsai S Y, Tsai M J, O’Malley B W. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily.  Science. 1995;  270 1354-1357
• 50 Anzick S L, Kononen J, Walker R L, Azorsa D O, Tanner M M, Guan X Y, Sauter G, Kallioniemi O P, Trent J M, Meltzer P S. A1131, a steroid receptor coactivator amplified in breast and ovarian cancer.  Science. 1997;  277 965-968
• 51 Li H, Gomes P J, Chen J D. RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2.  Proc Nati Acad Sci USA. 1997;  94 8479-8484
• 52 Voegel J J, Heine M J, Zechel C, Chambon P, Gronemeyer H. TIF2, a 160kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors.  Embo J. 1996;  15 3667-3675
• 53 Hanstein B, Eckner R, DiRenzo J, Halachmi S, Liu H, Searcy B, Kurokawa R, Brown M. p300 is a component of an oestrogen receptor coactivator complex.  Proc Natl Acad Sci USA. 1996;  93 11 540-11 545
• 54 Torchia J, Rose D W, Inostroza J, Kamei Y, Westin S, Glass C K, Rosenfeld M G. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function.  Nature. 1997;  387 677-684
• 55 Wehling M. Specific, nongenomic actions of steroid hormones.  Annu Rev Physiol. 1997;  59 365-393
• 56 Collins P, Webb C. Oestrogen hits the surface.  Nat Med. 1999;  5 1130-1131
• 57 Benten W P, Lieberherr M, Giese G, Wrehlke C, Stamm O, Sekeris C E, Mossmann H, Wunderlich F. Functional testosterone receptors in plasma membranes of T cells.  Faseb J. 1999;  13 123-133
• 58 Wehling M, Neylon C B, Fullerton M, Bobik A, Funder J W. Nongenomic effects of aldosterone on intracellular Ca²⁺ in vascular smooth muscle cells.  Circ Res. 1995;  76 973-979
• 59 Teschemacher A, Zeise M L, Holsboer F, Zieglgansberger W. The neuroactive steroid 5 alpha-tetrahydrodeoxycorticosterone increases GABAergic postsynaptic inhibition in rat neocortical neurons in vitro. .  J Neuroendocrinol. 1995;  7 233-240
• 60 Pietras R J, Szego C M. Endometrial cell calcium and oestrogen action.  Nature. 1975;  253 357-359
• 61 Mermelstein P G, Becker J B, Surmeier D J. Estradiol reduces calcium currents in rat neostriatal neurons via a membrane receptor.  J Neurosci. 1996;  16 595-604
• 62 Morley P, Whitfield J F, Vanderhyden B C, Tsang B K, Schwartz J L. A new, nongenomic oestrogen action: the rapid release of intracellular calcium.  Endocrinology. 1992;  131 1305-1312
• 63 Valverde M A, Rojas P, Amigo J, Cosmelli D, Orio P, Bahamonde M I, Mann G E, Vergara C, Latorre R. Acute activation of maxi-K channels (hSlo) by estradiol binding to the beta subunit.  Science. 1999;  285 1929-1931
• 64 Chen Z, Yuhanna I S, Galcheva-Gargova Z, Karas R H, Mendelsohn M E, Shaul P W. Oestrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by oestrogen (published erratum appears in J Clin Invest 1999 May; 103 (9): 1363).  J Clin Invest. 1999;  103 401-406
• 65 Norfleet A M, Thomas M L, Gametchu B, Watson C S. Oestrogen receptor-alpha detected on the plasma membrane of aldehyde-fixed GH3/B6/F10 rat pituitary tumor cells by enzyme-linked immunocytochemistry.  Endocrinology. 1999;  140 3805-3814
• 66 Razandi M, Pedram A, Greene G L, Levin E R. Cell membrane and nuclear oestrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells.  Mol Endocrinol. 1999;  13 307-319
• 67 Le Mellay V, Lasmoles F, Lieberherr M. Galpha(q/11) and gbetagamma proteins and membrane signaling of calcitriol and estradiol.  J Cell Biochem. 1999;  75 138-146
• 68 Improta-Brears T, Whorton A R, Codazzi F, York J D, Meyer T, McDonnell D ID. Oestrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium.  Proc Natl Acad Sci USA. 1999;  96 4686-4691
• 69 Lobenhofer EK Huper G, lglehart J D, Marks J R. Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents oestrogeninduced mitogenesis.  Cell Growth Differ. 2000;  11 99-110
• 70 Shyamala G, Barcellos-Hoff M H, Toft D, Yang X. In situ localization of progesterone receptors in normal mouse mammary glands: absence of receptors in the connective and adipose stroma and a heterogeneous distribution in the epithelium.  J Steroid Biochem Mol Biol. 1997;  63 251-259
• 71 . Early Breast Cancer Trialists’ Collaborative Group . Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women.  Lancet. 1992;  339 71-85
• 72 . Early Breast Cancer Trialists’ Collaborative Group . Ovarian ablation in early breast cancer - overview of the randomised trials.  Lancet. 1996;  348 1189-1196
• 73 Curtis R E, Boice J D Jr, Shriner D A, Hankey B F, Fraumeni J F Jr. Second cancers after adjuvant tamoxifen therapy for breast cancer.  J Natl Cancer Inst. 1996;  88 832-834
• 74 Muschen M, Moers C, Warskulat U, Niederacher D, Betz B, Even J, Lim A, Josien R, Beckmann M W, Haussinger D. CD95 ligand expression in dedifferentiated breast cancer.  J Pathol. 1999;  189 378-386
• 75 Dati C, Antoniofti S, Taverna D, Perroteau I, De Bortoli M. Inhibition of c-erbB-2 oncogene expression by oestrogens in human breast cancer cells.  Oncogene. 1990;  5 1001-1006
• 76 Gudas J M, Nguyen H, Li T, Cowan K H. Hormone-dependent regulation of BRCA1 in human breast cancer cells.  Cancer Res. 1995;  55 4561-4565
• 77 Zwijsen R M, Wientjens E, Klompmaker R, van der Sman J, Bernards R, Michalides R J. CDK-independent activation of oestrogen receptor by cyclin D1.  Cell. 1997;  88 405-415
• 78 Brzozowski A M, Pike A C, Dauter Z, Hubbard R, Bonn T, Engstrom O, Ohman L, Greene G L, Gustafsson J A, Cadquist M. Molecular basis of agonism and antagonism in the oestrogen receptor.  Nature. 1997;  16 753-758
• 79 Gelmann E P. Tamoxifen induction of apoptosis in oestrogen receptor-negative cancers: new tricks for an old dog?.  J Natl Cancer Inst. 1996;  88 224-226
• 80 Johnston S R, Haynes B P, Smith I E, Jarman M, Sacks N P, Ebbs S R, Dowsett M. Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration.  Lancet. 1993;  342 1521-1522
• 81 Gottardis M M, Jordan V C. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term anti-oestrogen administration.  Cancer Res. 1988;  148 5183-5187
• 82 Schwartz L B, Krey L, Demopoulos R, Goldstein S R, Nachtigall L E, Mittal K. Alterations in steroid hormone receptors in the tamoxifen-treated endometrium.  Am J Obstet Gynecol. 1997;  176 129-137
• 83 Webb P, Lopez G N, Uht R M, Kushner P J. Tamoxifen activation of the oestrogen receptor/AP-1 pathway: potential origin for the cell-specific oestrogen-like effects of antioestrogens.  Mol Endocrinol. 1995;  9 443-456